Evaluation of transport mechanism of prodrugs and parent drugs formed by intracellular metabolism in Caco-2 cells with modified carboxylesterase activity: Temocapril as a model case

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3985-3994

  Ohura, Kayoko ^a   Nozawa, Takaaki ^a   Murakami, Koichi ^a   Imai, Teruko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Caco 2 cells; Inhibition; Intestinal absorption; Membrane transport; Metabolism; Multidrug resistance associated proteins; P glycoprotein; Peptide transporters; Prodrugs; Transporters

Indexed keywords

4 NITROPHENYL PHOSPHATE; BREAST CANCER RESISTANCE PROTEIN; CARBOXYLESTERASE; ELACRIDAR; GLYCOPROTEIN P; NAPROXEN; PEPTIDE TRANSPORTER 1; PROPRANOLOL; SERINE DEHYDRATASE; TEMOCAPRIL; TEMOCAPRILAT;

APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CELL MEMBRANE; CELL METABOLISM; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROLYSIS; INTESTINE ABSORPTION; MICROVILLUS; MONOLAYER CULTURE;

EID: 79960143955     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22628     Document Type: Article

References (41)

1. Artursson P, Palm K, Luthman K. 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43.
2. Lennernäs H. 1998. Human intestinal permeability. J Pharm Sci 87:403-410.
3. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. 1997. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha, 25-dihydroxyvitamin D3. Mol Pharmacol 51:741-754.
4. Imai T, Imoto M, Sakamoto H, Hashimoto M. 2005. Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug Metab Dispos 33:1185-1190.
5. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. 2002. Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493.
6. Imai T. 2006. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21(3):173-185.
7. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. 2000. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60:1189-1192.
8. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, Yan B. 2006. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467-1476.
9. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B. 2006. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319:1477-1484.
10. Fujiyama N, Miura M, Kato S, Sone T, Isobe M, Satoh S. 2010. Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos 38:2210-2217.
11. Takai S, Matsuda A, Usami Y, Adachi T, Sugiyama T, Katagiri Y, Tatematsu M, Hirano K. 1997. Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull 20:869-873.
12. Imai T, Hosokawa M. 2010. Prodrug approach using carboxylesterases activity: catalytic properties and gene regulation of carboxylesterase in mammalian tissue. J Pestic Sci 35:229-239.
13. Ohura K, Sakamoto H, Ninomiya S, Imai T. 2010. Development of a novel system for estimating human intestinal absorption using Caco-2 cells in the absence of esterase activity. Drug Metab Dispos 38:323-331.
14. Heymann E, Krisch K. 1967. Phosphoric acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxylesterases. Hoppe Seylers Z Physiol Chem 348:609-619.
15. 14C]phenylphosphate as carboxylesterases and amidases. Biochim Biophys Acta 524:85-93.
16. Mentlein R, Rix-Matzen H, Heymann E. 1988. Subcellular localization of non-specific carboxylesterases, acylcarnitine hydrolase, monoacylglycerol lipase and palmitoyl-CoA hydrolase in rat liver. Biochim Biophys Acta 964:319-328.
17. Masaki K, Taketani M, and Imai T. 2006. First-pass hydrolysis of a propranolol ester derivative in rat small intestine. Drug Metab Dispos 34:398-404.
18. Pade V, Stavchansky S. 1998. Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci 87:1604-1607.
19. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
20. Vistoli G., Pedretti A, Mazzolari A, Bolchi C, Testa B. 2009. Influence of ionization state on the activation of temocapril by hCES1: a molecular-dynamics study. Chem Biodivers 6: 2092-2100.
21. Nakanishi T, Tamai I, Sai Y, Sasaki T, Tsuji A. 1997. Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res 57:4118-4122.
22. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. 2002. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164-172.
23. Matsson P, Pedersen JM, Norinder U, Bergström CA, Artursson P. 2009. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816-1831.
24. Dahan A, Amidon GL. 2008. Segmental Dependent Transport of Low Permeability Compounds along the Small Intestine Due to P-Glycoprotein: The Role of Efflux Transport in the Oral Absorption of BCS Class III Drugs. Mol Pharm 6:19-28.
25. Laiko M, Murtazina R, Malyukova I, Zhu C, Boedeker EC, Gutsal O, O'Malley R, Cole RN, Tarr PI, Murray KF, Kane A, Donowitz M, Kovbasnjuk O. 2010. Shiga toxin 1 interaction with enterocytes causes apical protein mistargeting through the depletion of intracellular galectin-3. Exp Cell Res 316:657-666.
26. Ikeda I, Matsuoka R, Hamada T, Mitsui K, Imabayashi S, Uchino A, Sato M, Kuwano E, Itamura T, Yamada K, Tanaka K, Imaizumi K. 2002. Cholesterol esterase accelerates intestinal cholesterol absorption. Biochim Biophys Acta 1571:34-44.
27. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. 2006. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 281:36569-36578.
28. Grès MC, Julian B, Bourrié M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, and Fabre G. 1998. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 15:726-733.
29. Püchler K, Sierakowski B, Roots I. 1998. Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients. Br J Clin Pharmacol 46:363-367.
30. Ishizuka H, Konno K, Naganuma H, Sasahara K, Kawahara Y, Niinuma K, Suzuki H, Sugiyama Y. 1997. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J Pharmacol Exp Ther 280:1304-1311.
31. Shionoiri H, Takasaki I, Minamisawa K, Ishizuka H, Konno K, Naganuma H, Sasahara K, Kawahara Y. 2001. Trandolaprilat, an angiotensin-converting enzyme inhibitor, is not excreted in bile via an ATP-dependent active transporter (cMOAT). Hypertens Res 24:235-240.
32. Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, Suzuki H, Stieger B, Meier PJ, Sugiyama Y. 1998. Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. J Pharmacol Exp Ther 287:37-42.
33. Hasegawa M, Kusuhara H, Endou H, Sugiyama Y. 2003. Contribution of organic anion transporters to the renal uptake of anionic compounds and nucleoside derivatives in rat. J Pharmacol Exp Ther 305:1087-1097.
34. Yang CY, Dantzig AH, Pidgeon C. 1999. Intestinal peptide transport systems and oral drug availability. Pharm Res 16:1331-1343.
35. Lee VH. 2000. Membrane transporters. Eur J Pharm Sci 112:S41-50.
36. Knütter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M. 2008. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther 327:432-441.
37. Thwaites DT, Cavet M, Hirst BH, Simmons NL. 1995. Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells. Br J Pharmacol 114:981-986.
38. Nozawa T, Imai T. 2011. Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity. Drug Metab Dispos Fast Forward Articles, April 7:2011.
39. Imai T, Ohura K. 2010. The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr Drug Metab 11:793-805.
40. Faber KN, Müller M, Jansen PL. 2003. Drug transport proteins in the liver. Adv Drug Deliv Rev 55:107-124.
41. Sai Y, Tsuji A. 2004. Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov Today 9:712-120.